Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CorMedix Inc. stock logo
CRMD
CorMedix
$12.09
-2.7%
$9.16
$3.61
$13.85
$820.55M1.541.16 million shs378,912 shs
CureVac stock logo
CVAC
CureVac
$4.73
+6.6%
$3.32
$2.37
$5.28
$1.06B2.43743,597 shs317,422 shs
MediWound Ltd. stock logo
MDWD
MediWound
$21.35
+1.3%
$17.68
$12.78
$24.00
$230.70M0.391,006 shs9,527 shs
Pharvaris stock logo
PHVS
Pharvaris
$16.62
+7.5%
$15.40
$11.51
$25.50
$879.52M-2.8572,686 shs33,041 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CorMedix Inc. stock logo
CRMD
CorMedix
-0.80%+1.14%+37.20%+21.27%+131.90%
CureVac stock logo
CVAC
CureVac
+2.07%+13.85%+27.95%+45.10%+20.98%
MediWound Ltd. stock logo
MDWD
MediWound
-1.13%+5.98%+15.25%+29.88%+18.49%
Pharvaris stock logo
PHVS
Pharvaris
-2.40%-5.73%-9.38%-0.64%-21.32%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CorMedix Inc. stock logo
CRMD
CorMedix
2.0118 of 5 stars
3.61.00.00.04.00.00.6
CureVac stock logo
CVAC
CureVac
4.0039 of 5 stars
3.52.00.04.82.70.01.3
MediWound Ltd. stock logo
MDWD
MediWound
1.913 of 5 stars
3.52.00.00.02.00.80.6
Pharvaris stock logo
PHVS
Pharvaris
2.1504 of 5 stars
3.53.00.00.03.10.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CorMedix Inc. stock logo
CRMD
CorMedix
3.14
Buy$15.0024.07% Upside
CureVac stock logo
CVAC
CureVac
3.00
Buy$11.00132.51% Upside
MediWound Ltd. stock logo
MDWD
MediWound
3.00
Buy$31.2546.40% Upside
Pharvaris stock logo
PHVS
Pharvaris
3.00
Buy$40.67144.69% Upside

Current Analyst Ratings Breakdown

Latest MDWD, PHVS, CVAC, and CRMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
CureVac stock logo
CVAC
CureVac
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$10.00
5/22/2025
MediWound Ltd. stock logo
MDWD
MediWound
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$25.00 ➝ $31.00
5/14/2025
Pharvaris stock logo
PHVS
Pharvaris
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$28.00 ➝ $25.00
5/7/2025
CorMedix Inc. stock logo
CRMD
CorMedix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $15.00
5/6/2025
CorMedix Inc. stock logo
CRMD
CorMedix
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/2/2025
MediWound Ltd. stock logo
MDWD
MediWound
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00
4/30/2025
CureVac stock logo
CVAC
CureVac
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $12.00
4/29/2025
Pharvaris stock logo
PHVS
Pharvaris
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$28.00
4/9/2025
CorMedix Inc. stock logo
CRMD
CorMedix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
4/8/2025
CorMedix Inc. stock logo
CRMD
CorMedix
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/26/2025
CorMedix Inc. stock logo
CRMD
CorMedix
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$12.00 ➝ $12.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CorMedix Inc. stock logo
CRMD
CorMedix
$82.55M9.93N/AN/A$1.28 per share9.45
CureVac stock logo
CVAC
CureVac
$523.70M2.03N/AN/A$2.50 per share1.89
MediWound Ltd. stock logo
MDWD
MediWound
$19.21M12.01N/AN/A$3.43 per share6.22
Pharvaris stock logo
PHVS
Pharvaris
N/AN/AN/AN/A$7.95 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CorMedix Inc. stock logo
CRMD
CorMedix
-$46.34M$0.22N/A12.86N/AN/A-79.21%-64.68%8/13/2025 (Estimated)
CureVac stock logo
CVAC
CureVac
-$281.58M$0.928.55N/AN/A20.72%21.98%15.72%8/13/2025 (Estimated)
MediWound Ltd. stock logo
MDWD
MediWound
-$6.72M-$2.09N/AN/AN/A-142.29%-82.17%-33.67%8/13/2025 (Estimated)
Pharvaris stock logo
PHVS
Pharvaris
-$109.18M-$3.01N/AN/AN/AN/A-38.52%-36.69%8/13/2025 (Estimated)

Latest MDWD, PHVS, CVAC, and CRMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/22/2025Q1 2025
CureVac stock logo
CVAC
CureVac
-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million
5/21/2025Q1 2025
MediWound Ltd. stock logo
MDWD
MediWound
-$0.65-$0.07+$0.58-$0.07$5.20 million$3.96 million
5/13/2025Q1 2025
Pharvaris stock logo
PHVS
Pharvaris
-$0.80-$0.89-$0.09-$0.89N/AN/A
5/6/2025Q1 2025
CorMedix Inc. stock logo
CRMD
CorMedix
$0.25$0.30+$0.05$0.30$38.90 million$39.08 million
4/10/2025Q4 2024
CureVac stock logo
CVAC
CureVac
-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million
4/7/2025Q4 2024
Pharvaris stock logo
PHVS
Pharvaris
-$0.74-$0.68+$0.06-$0.68N/AN/A
3/25/2025Q4 2024
CorMedix Inc. stock logo
CRMD
CorMedix
$0.17$0.22+$0.05$0.22$27.46 million$30.00 million
3/19/2025Q4 2024
MediWound Ltd. stock logo
MDWD
MediWound
-$0.59-$0.36+$0.23-$0.36$5.79 million$5.84 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CorMedix Inc. stock logo
CRMD
CorMedix
N/AN/AN/AN/AN/A
CureVac stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
MediWound Ltd. stock logo
MDWD
MediWound
N/AN/AN/AN/AN/A
Pharvaris stock logo
PHVS
Pharvaris
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CorMedix Inc. stock logo
CRMD
CorMedix
N/A
3.96
3.60
CureVac stock logo
CVAC
CureVac
0.05
6.20
6.19
MediWound Ltd. stock logo
MDWD
MediWound
N/A
2.11
1.99
Pharvaris stock logo
PHVS
Pharvaris
N/A
19.08
19.08

Institutional Ownership

CompanyInstitutional Ownership
CorMedix Inc. stock logo
CRMD
CorMedix
34.18%
CureVac stock logo
CVAC
CureVac
17.26%
MediWound Ltd. stock logo
MDWD
MediWound
46.83%
Pharvaris stock logo
PHVS
Pharvaris
N/A

Insider Ownership

CompanyInsider Ownership
CorMedix Inc. stock logo
CRMD
CorMedix
5.20%
CureVac stock logo
CVAC
CureVac
2.15%
MediWound Ltd. stock logo
MDWD
MediWound
9.20%
Pharvaris stock logo
PHVS
Pharvaris
11.84%
CompanyEmployeesShares OutstandingFree FloatOptionable
CorMedix Inc. stock logo
CRMD
CorMedix
3067.83 million57.52 millionOptionable
CureVac stock logo
CVAC
CureVac
880224.34 million219.07 millionOptionable
MediWound Ltd. stock logo
MDWD
MediWound
8010.81 million9.79 millionOptionable
Pharvaris stock logo
PHVS
Pharvaris
3052.29 million46.10 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CorMedix stock logo

CorMedix NASDAQ:CRMD

$12.09 -0.34 (-2.74%)
As of 11:46 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CureVac stock logo

CureVac NASDAQ:CVAC

$4.73 +0.29 (+6.55%)
As of 11:45 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

MediWound stock logo

MediWound NASDAQ:MDWD

$21.34 +0.27 (+1.26%)
As of 11:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Pharvaris stock logo

Pharvaris NASDAQ:PHVS

$16.62 +1.16 (+7.50%)
As of 11:44 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.